



Date 22 November 2016

Sydney, Australia

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office:**

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

## **CORPORATE PRESENTATION PROVIDING CLINICAL PROGRAM GUIDANCE**

- **5 clinical studies planned**
- **Objective to provide proof-of-concept by end of 2017**
- **5 R&D projects activated**

Noxopharm Limited (ASX: NOX) today posts its latest corporate presentation ahead of its AGM on 23 November 2016.

Dr Kelly, Noxopharm CEO, said, "The Company has embarked on an ambitious clinical trials program across a range of cancer types and in combination with chemotherapy or radiotherapy. The objectives are (a) to give ourselves the best chance to identify the best clinical indications to be pursued in registration studies, and (b) to provide evidence of proof-of-concept by the end of 2017."

The clinical trials include a mix of Investigator-Initiated and Sponsor-Initiated clinical studies and have been costed to be within the Company's current budget.

### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

### **About NOX66**

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in an active form. Idronoxil works by cancelling pro-survival mechanisms in cancer cells regulated by sphingosine-1-phosphate that allow the cells to resist the killing effects of chemotherapies and radiotherapy.

**INVESTOR AND MEDIA ENQUIRIES:**  
**E: [info@noxopharm.com](mailto:info@noxopharm.com)**

**Prue Kelly**  
**T: + 61 2 9144 2223**

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.